Research programme: cell therapy for heart disease - Columbia University/Boston Scientific/Stony Brook

Drug Profile

Research programme: cell therapy for heart disease - Columbia University/Boston Scientific/Stony Brook

Alternative Names: Cell-based biological pacemaker

Latest Information Update: 31 Aug 2009

Price : $50

At a glance

  • Originator Boston Scientific Corporation; Columbia University; State University of New York at Stony Brook
  • Developer Boston Scientific Corporation; Columbia University
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Conduction disorders

Most Recent Events

  • 28 Aug 2009 Preclinical development is ongoing in USA
  • 22 Aug 2007 Preclinical development is ongoing
  • 30 Aug 2004 Preclinical trials in Arrhythmias in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top